BNX-E4

N/A

Report date: 2025/11/03 16:30:04

Base Information

Drug NameBNX-E4

Drug Alias NameBNX-E4

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsPolyarticular Juvenile Idiopathic Arthritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBionoxx Inc

China Registration ClassN/A

Develop Information

Active CompaniesBionoxx Inc

Inactive CompaniesN/A

Active IndicationsPolyarticular Juvenile Idiopathic Arthritis

Inactive IndicationsN/A

Other Information

ATC CodeN/A